Debra King Sells 826 Shares of Stryker (NYSE:SYK) Stock

Stryker Corporation (NYSE:SYK) insider Debra King sold 826 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This represents a 11.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Stryker Price Performance

Shares of NYSE:SYK opened at $340.20 on Thursday. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $130.49 billion, a PE ratio of 35.25, a price-to-earnings-growth ratio of 2.11 and a beta of 0.76. The firm’s 50 day moving average price is $326.19 and its 200-day moving average price is $332.95. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $396.86.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same period in the previous year, the business posted $3.13 earnings per share. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts expect that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. Stryker’s payout ratio is presently 36.48%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Gables Capital Management Inc. purchased a new position in shares of Stryker in the second quarter worth $25,000. Kilter Group LLC bought a new stake in Stryker in the 2nd quarter valued at $25,000. Godfrey Financial Associates Inc. bought a new stake in Stryker in the 4th quarter valued at $26,000. Sankala Group LLC purchased a new stake in Stryker in the 4th quarter worth $26,000. Finally, Compass Financial Management LLC purchased a new stake in Stryker in the 2nd quarter worth $27,000. 77.09% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Evercore set a $350.00 target price on Stryker in a research report on Monday, July 6th. Leerink Partners decreased their price objective on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research note on Friday, June 5th. Sanford C. Bernstein set a $410.00 price objective on Stryker in a research report on Friday, May 1st. BTIG Research cut their price objective on Stryker from $371.00 to $358.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Finally, Wells Fargo & Company reduced their target price on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.